Camizestrant is an investigational new drug that is being evaluated to treat breast cancer. It is an estrogen receptor alpha antagonist and a selective estrogen receptor degrader. From Wikipedia
Liquid biopsy-guided treatment extended progression-free survival from nine to 16 months
